First, our findings provide a potential alternative, the use of miR-337-3p mimic, to target STAT3. Second, our findings provide support for combining STAT3 inhibitors with paclitaxel in order to improve response to lung cancer treatment. The gene discussed is STAT3; the disease is lung cancer.